NL-OMON49517招募中2 期
ow dose iron chelation as TReatment of Oxidative stress in Sickle cell disease; TROS study - TROS study
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Sickle cell disease diagnosis: HbSS, or HbSβ0-thalassemia genotype
- •2. Age 18-65 years
- •3. Willing and able to provide written informed consent
排除标准
- •1. Blood transfusion in the preceding four months
- •2. Already using iron chelation due to iron overload
- •3. Ferritin levels of <50 µg/L and/or transferrin saturation of < 0.20.
- •4. LDH of < 300 U/L
- •5. Pregnancy or the desire to get pregnant in the following 6 months
- •6. Impaired renal function of GFR < 60 ml/min/1,73m2 (CKD-EPI).
- •7. Known allergic reaction to deferasirox.
- •8. Other somatic or cognitive condition disturbing adherence to study treatment
研究者
相似试验
进行中（未招募）
1 期
Iron lowering treatment to reduce tissue damage in sickle cell diseaseSickle cell disease (an hereditary hemoglobinopathy)EUCTR2020-004995-17-NLAMsterdam UMC-AMC30
尚未招募
不适用
ow dose iron chelation as TReatment of Oxidative damage in Sickle cell diseaseSickle cell diseaseNL-OMON20240Amsterdam UMC location AMC.10
招募中
不适用
Evaluation of iron chelator administration, and cochlear implantation for superficial siderosisJPRN-jRCTs031180438Sanjo Nobuo50
进行中（未招募）
1 期
ew therapeutic strategy in Parkinson’s diseaseDe Novo Parkinson’s diseaseEUCTR2015-003679-31-FRCentre Hospitalier Régional et Universitaire de Lille338
进行中（未招募）
1 期
ew therapeutic strategy in Parkinson?s diseaseDe Novo Parkinson?s diseaseMedDRA version: 18.1Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-003679-31-ESCentre Hospitalier Régional et Universitaire de Lille338